Research ArticleArticle
Hepatic Uptake of Atorvastatin: Influence of Variability in Transporter Expression on Uptake Clearance and Drug-Drug Interactions
Anna Vildhede, Maria Karlgren, Elin K. Svedberg, Jacek R. Wisniewski, Yurong Lai, Agneta Norén and Per Artursson
Drug Metabolism and Disposition July 2014, 42 (7) 1210-1218; DOI: https://doi.org/10.1124/dmd.113.056309
Anna Vildhede
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Maria Karlgren
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Elin K. Svedberg
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Jacek R. Wisniewski
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Yurong Lai
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Agneta Norén
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Per Artursson
Department of Pharmacy, Uppsala University, Uppsala, Sweden (A.V., M.K., E.K.S., P.A.); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Chemical Biology Consortium Sweden (M.K., P.A.), Uppsala, Sweden; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany (J.R.W.); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut (Y.L.); and Department of Surgery, Uppsala University, Uppsala, Sweden (A.N.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Interindividual Variability in Hepatic Atorvastatin Uptake
Anna Vildhede, Maria Karlgren, Elin K. Svedberg, Jacek R. Wisniewski, Yurong Lai, Agneta Norén and Per Artursson
Drug Metabolism and Disposition July 1, 2014, 42 (7) 1210-1218; DOI: https://doi.org/10.1124/dmd.113.056309
Research ArticleArticle
Interindividual Variability in Hepatic Atorvastatin Uptake
Anna Vildhede, Maria Karlgren, Elin K. Svedberg, Jacek R. Wisniewski, Yurong Lai, Agneta Norén and Per Artursson
Drug Metabolism and Disposition July 1, 2014, 42 (7) 1210-1218; DOI: https://doi.org/10.1124/dmd.113.056309
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement